Browse EX-10 agreements

---

Exhibit 10.26

Execution Version

CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT

This Convertible Promissory Note Purchase Agreement (“Agreement”) is entered into as of June 24, 2026, by and among Remix Therapeutics, Inc., a Delaware corporation (the “Company”), and the lenders (each individually, a “Lender”, and collectively, the “Lenders” named on the Schedule of Lenders attached hereto as Exhibit A (the “Schedule of Lenders”) and any additional Lenders who become party hereto.  The Company and the Lenders may be referred to herein individually as a “Party” and, collectively, as the “Parties”.  Capitalized terms not otherwise defined in this Agreement shall have the meanings ascribed to them in Section 1 below.

WHEREAS, the Parties wish to provide for the sale and issuance of Notes, as defined below, to the Lenders by the Company in return for the provision by the Lenders of the loan amounts to the Company as set forth for each Lender on the Schedule of Lenders; and

…

---

Exhibit 10.33

REMIX THERAPEUTICS INC.

Aug 1, 2019

Dear Peter:

Remix Therapeutics Inc. (the “Company”), is pleased to offer you employment on the following terms:

1.            Position.  Your title will be President and Chief Scientific Officer, and you will report to the Company’s Board of Directors (the “Board”).  This is a full-time position.  You will undertake to perform, to the best of your ability, all the work related to the Company’s business that can reasonably be assigned to you by or on behalf of the Company consistent with this position.  You will act in accordance with the instructions to be given to you by the Board.  While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) without the prior consent of the Board and under no circumstances will you engage in activities that would create a conflict of interest with the Company.  For the avoidance of doubt, the Company agrees that you may continue (i) in a consulting or advisory board capacity with Rodin Therapeu

…

---

Exhibit 10.31

REMIX THERAPEUTICS INC.

2019 STOCK PLAN

ADOPTED ON JULY 26, 2019

---

TABLE OF CONTENTS

Page

SECTION 1.		ESTABLISHMENT AND PURPOSE	1
SECTION 2.		ADMINISTRATION	1
	(a)	Committees of the Board of Directors	1
	(b)	Authority of the Board of Directors	1
SECTION 3.		ELIGIBILITY	1
	(a)	General Rule	1
	(b)	Ten‑Percent Stockholders	1

…

---

Exhibit 10.34

Remix Therapeutics, Inc.

400 Technology Square

Cambridge, MA  02139

August 3rd, 2020

Dear Heather:

Remix Therapeutics, Inc.  (the “Company”) is pleased to offer you employment on the following terms:

1.          Position.  Your initial title will be Chief Business Officer/Chief Operating Officer, and you will initially report to Peter Smith, the Company’s President and Chief Scientific Officer.  This is a full-time position.  You are required to relocate to, and maintain a residence in, the greater Boston area.  While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full‑time or part-time) without the Company’s prior written consent.  By signing this letter agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.

…

---

Exhibit 10.35

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the Registrant as private or confidential.

Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.

TEMPUS

Master Agreement

This Master Agreement (the “Agreement”) is entered into by and between Tempus Labs, Inc., with its principal place of business at 600 West Chicago Ave., Suite 510, Chicago, IL 60654 (on behalf of itself and its affiliates, “Tempus”) and Remix Therapeutics Inc., with its principal place of business at 100 Forge Road, Watertown MA 02472 (“Client”). Tempus and Client are each individually a “Party” and are collectively the “Parties.”

Background

…

---

Exhibit 10.30

Portions of this exhibit, indicated by [***], have been omitted in accordance with Item 601(b)(10) (iv) of Regulation S-K. The omitted information is (i) not material and (ii) treated by the Registrant as private or confidential.

Portions of this exhibit have been omitted in accordance with Item 601(a)(5) of Regulation S-K.

The Registrant undertakes to furnish a copy of all omitted information, schedules, and exhibits to the U.S. Securities and Exchange Commission upon its request.

---

*
*

LEASE

From

100 FORGE HOLDING LLC,

Landlord

To

REMIX THERAPEUTICS INC.,

Tenant

100 Forge Road, Watertown, Massachusetts

---

TABLE OF CONTENTS

Page

…

---

Exhibit 10.32

REMIX THERAPEUTICS, INC.

25th July 2019

PERSONAL AND CONFIDENTIAL

Dear Dominic

Remix Therapeutics, Inc. (the “Company”) is pleased to offer you the full-time position of Vice President.  We are excited about the prospect of you joining our team, and look forward to the addition of your professionalism and experience to help the Company achieve its goals.  As a full-time employee, you are expected to devote your full time and best efforts to the Company, and you may not engage in outside business activities without the Company’s prior written consent.  Notwithstanding the foregoing, the Company acknowledges that, in the first year of your employment, you may engage in consulting or other business activities for other portfolio companies of Atlas Ventures (“Atlas”) up to a maximum of 25% of your business time, with the prior agreement of the Chief Scientific Officer.

…

INVESTMENT MANAGEMENT TRUST AGREEMENT

This Investment Management Trust Agreement (this “Agreement”) is made effective as of __________, 2026 by and between Pine Tree Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”).

WHEREAS, the Company’s registration statement on Form S-1 (File No. 333-292289) (the “Registration Statement”) and prospectus (the “Prospectus”) for the initial public offering (the “Offering”) of the Company’s units (the “Units”), each of which consists of one Class A ordinary share, par value $0.0001 per share (the “Shares”), and one right entitling the holder thereof to receive one-fourth of one Share upon the completion of an initial Business Combination (as defined below), has been declared effective as of the date hereof by the U.S. Securities and Exchange Commission; and

…

REGISTRATION RIGHTS AGREEMENT

THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of ___________, 2026, is made and entered into by and among Pine Tree Acquisition Corp., a Cayman Islands exempted company (the “Company”), Pine Tree Sponsor Group, LLC, a Delaware limited liability company (“Pine Tree Group”), and North Penn, LLC, a Delaware limited liability company (“North Penn” and collectively with Pine Tree Group, the “Sponsors”), Maxim Group LLC (the “Representative”) and each of the undersigned parties listed on the signature page hereto under “Holders” (each such party, together with the Sponsors, the Representative and any person or entity who hereafter becomes a party to this Agreement pursuant to Section 5.2 of this Agreement, a “Holder” and collectively the “Holders”).

RECITALS

…

PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT

THIS PRIVATE PLACEMENT UNITS PURCHASE AGREEMENT, dated as of ________, 2026 (as it may from time to time be amended and including all exhibits referenced herein, this “Agreement”), is entered into by and Pine Tree Acquisition Corp., a Cayman Islands exempted company (the “Company”), and [Pine Tree Sponsor Group, LLC][North Penn, LLC] (the “Purchaser”).

WHEREAS, the Company intends to consummate an initial public offering (the “Public Offering”) of the Company’s units (the “Public Units”), each Public Unit consisting of one Class A ordinary share of the Company, par value $0.0001 per share (each, a “Share”) and one right entitling the holder thereof to receive one-fourth of one Share upon the completion of an initial business combination (each, a “Right”).

WHEREAS, the Purchaser has agreed to purchase an aggregate of _____ units (the “Private Placement Units”) concurrently with the closing of the Public Offering.

…

**  EXHIBIT 10.1**

_______________, 2026

Pine Tree Acquisition Corp.

418 Broadway, #6538

Albany, NY 12207

Re: Initial Public Offering

Ladies and Gentlemen:

This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) entered into by and between Pine Tree Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Maxim Group LLC as representative (the “Representative”) of the underwriters (the “Underwriters”), relating to an underwritten initial public offering (the “Public Offering”) of up to 11,500,000 of the Company’s units (including up to 1,500,000 units which may be purchased to cover over-allotments, if any) (the “Units”), each comprised of one Class A ordinary share, par value $0.0001 per share, of the Company (the “Class A Ordinary Shares”), and one right (the “Rights”). Each Right entitles the holder to receive one-fourth of one Class A Ordinary Share upon consummation of a Business Combination (defined b

…

** **

JET.AI INC

2023 AMENDED AND RESTATED OMNIBUS INCENTIVE PLAN

RESTRICTED STOCK AWARD

Dear * *_____________________:

You have been granted an award of common stock of Jet.AI Inc. (the “Company”) constituting a Restricted Stock Award (the “Award”) under the 2023 Jet.AI Inc. Amended and Restated Omnibus Incentive Plan (the “Plan”), effective as of the Grant Date, the terms and conditions described herein. The grant of the Restricted Stock is made in consideration of the services to be rendered by you to the Company.

…